Formulations and Characterization of Liquid SMEDDS of Dexlansoprazole
Abstract
Dexlansoprazole is a second-generation proton pump inhibitor (PPI) used in the treatment ofsymptoms of gastroesophageal reflux disease (GERD) and erosive esophagitis (esophageal damage caused by acid in stomach), but because of poor solubility, stability and oral bioavailability. The objective of our research was to formulate a self-micro emulsifying drug delivery system (SMEDDS) of Dexlansorazole by minimum surfactant concentration which would improve its solubility, stability and oral bioavailability. Optimized formula [C7IIB] composition includes Capryol 90 as oil, Labrasol as surfactant and Captex 500 as cosurfactant containing 30 mg of Dexlansoprazole showing drug release for liquid SMEDDS formulation (99.9%), droplet size (9.10 nm), Zeta potential (-23.9), viscosity (0.9141 cP) and infinite dilution capacity. In-vitro drug release of C7IIB was extremely high (p <0.05) compared with marketed conventional capsules (M). C7IIB was also employed to develop various SMEDDS formulations (Powder-filled capsule).
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.